Varicella vaccination in Italy: An economic evaluation of different scenarios

PharmacoEconomics

Volumn 22, Issue 13, 2004, Pages 839-855

  Coudeville, Laurent ^a   Brunot, Alain ^a   Giaquinto, Carlo ^b   Lucioni, Carlo ^c   Dervaux, Benoit ^a,d  

^a UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^b UNIVERSITY OF PADOVA   (Italy)

^c Adis International Ltd   (Italy)

^d CRESGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; NON PRESCRIPTION DRUG;

ARTICLE; CHICKENPOX; CHILD CARE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MARKETING; ECONOMIC EVALUATION; EPIDEMIOLOGICAL DATA; FATALITY; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; ITALY; MEDICAL FEE; PRIORITY JOURNAL; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; DRUG COSTS; HUMANS; INFANT; ITALY; MASS IMMUNIZATION; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; VACCINES, ATTENUATED;

EID: 4644276801     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422130-00003     Document Type: Article

References (63)

1. Gabutti G, Penna C, Rossi M, et al. The seroepidemiology of varicella in Italy. Epidemiol Infect 2001; 126 (3): 433-40
2. Deguen S, Chau NP, Flahault A. Epidemiology of chickenpox in France (1991-1995). J Epidemiol Community Health 1998; 52 Suppl. 1: 46S-9S
3. Choo PW, Donahue JG, Manson JE, et al. The epidemiology of varicella and its complications. J Infect Dis 1995; 172 (3): 706-12
4. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr 1997; 130 (5): 759-65
5. Meyer PA, Seward JF, Jumaan AO, et al. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000; 182 (2): 383-90
6. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; II (7892): 1288-90
7. Barker L, Luman E, Zhao Z, et al. National, state, and urban area vaccination coverage levels among children aged 19-35 months: United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51 (30): 664-6
8. Caraffa De Stefano D, Vellucci L. Proposte per la raccomandazione della vaccinazione antivaricella in Italia. Ann Ig 2002; 14 (4 Suppl. 6): 67-8
9. Germinario C, Lopalco PL, Prato R, et al. Target della vaccinazione antivaricella. Ann Ig 2002; 14 (4 Suppl. 6): 55-8
10. Salmaso S, Mandolini D, Scalia Tomba G, et al. La prevenzione della varicella in Italia: strategie di vaccinazione. Ann Ig 2002; 14 (4 Suppl. 6): 35-44
11. Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003; 21 (11-12): 1256-67
12. Beutels P, Clara R, Tormans G, et al. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174 Suppl. 3: S335-41
13. Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17 (2): 142-51
14. Diez Domingo J, Ridao M, Latour J, et al. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17 (11-12): 1306-11
15. Gray AM, Fenn P, Weinberg J, et al. An economic analysis of varicella vaccination for health care workers. Epidemiol Infect 1997; 119 (2): 209-20
16. O'Neill J, Buttery J. Varicella and paediatric staff: current practice and vaccine cost-effectiveness. J Hosp Infect 2003; 53 (2): 117-9
17. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20 (7-8): 1113-25
18. Getsios D, Caro JJ, Caro G, et al. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J 2002; 21 (6): 542-7
19. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programmes for Australia. Vaccine 1999; 18 (5-6): 407-15
20. Scuffham P, Devlin N, Eberhart-Phillips J, et al. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med 1999; 49 (6): 763-79
21. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271 (5): 375-81
22. Huse DM, Meissner HC, Lacey MJ, et al. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994; 124 (6): 869-74
23. Burnham BR, Wells TS, Riddle JR. A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets. Mil Med 1998; 163 (9): 631-4
24. Zotti CM, Maggiorotto G, Migliardi A. I costi della varicella. Ann Ig 2002; 14 (4 Suppl. 6): 29-33
25. Fornaro P, Gandini F, Marin M, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Italian Sentinel Group on Pediatric Infectious Diseases. Pediatr Infect Dis J 1999; 18 (5): 414-9
26. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003; 88 (10): 862-9
27. Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140 (2): 81-104
28. Halloran ME. Epidemiologic effects of varicella vaccination. Inf Dis Clin North Am 1996; 10 (3): 631-55
29. ISTAT. Annuario Statistico Italiano; 2001 [online]. Available from URL: http://www.istat.it [Accessed 2001 December]
30. Salmaso S, Rota M, Ciofi Degli Atti L, et al. Infant immunization coverage in Italy: estimates by simultaneous EPI cluster surveys of regions. Bull World Health Organ 1999; 77 (10): 843-51
31. Brisson M, Edmunds WJ, Gay NJ, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125 (3): 651-69
32. Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr 2001; 139 (2): 297-304
33. Giaquinto C, Sturkenboom M, Mannino S, et al. Epidemiologia ed esiti della varicella in Italia: risultati di uno studio prospettico sui bambini (0-14 anni) seguiti dai pediatri di libera scelta (studio pedianet). Ann Ig 2002; 14 (4 Suppl. 6): 21-7
34. Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 2001; 323 (7321): 1091-3
35. Grenfell BT, Anderson RM. The estimation of age-related rates of infection from case notifications and serological data. J Hyg (Lond) 1985; 95 (2): 419-36
36. Johansson LA, Westerling R. Comparing hospital discharge records with death certificates: can the differences be explained? J Epidemiol Community Health 2002 Apr; 56 (4): 301-8
37. Messite J, Stellman SD. Accuracy of death certificate completion: the need for formalized physician training. JAMA 1996 Mar 13; 275 (10): 794-6
38. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19 (7-8): 916-23
39. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278 (18): 1495-9
40. Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999; 18 (12): 1041-6
41. Drummond MF, Stoddard GL. Methods for the economic evaluations of health care programmes. Oxford: Oxford University Press, 1987
42. Lucioni C, Cirrimina S, Di Carlo P, et al. Il costo sociale del morbillo in éta pediatrica: l'epidemia a Palermo nel 1996-97. Pharmacoeconomics Italian Research Articles 1999; 1 (1): 17-33
43. Gruppo di lavoro ICONA. Indagine nazionale sulla copertura vaccinale infantile. Rapporto ISTISAN (Isituto Superiore di Sanita) 1998; 98/33 (viii): 123
44. Lieu TA, Black SB, Takahashi H, et al. Varicella serology among school age children with a negative or uncertain history of chickenpox. Pediatr Infect Dis J 1998 Feb; 17 (2): 120-5
45. Harel Z, Ipp L, Riggs S, et al. Serotesting versus presumptive varicella vaccination of adolescents with a negative or uncertain history of chickenpox. J Adolesc Health 2001; 28: 26-9
46. Garattini L, Grilli R, Scopelliti D, et al. A proposal for Italian Guidelines in pharmacoeconomics. Pharmacoeconomics 1995; 7: 1-6
47. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5 (2): 157-77
48. Walter EB, Simmons SS, Bland CL, et al. Modified varicella-like syndrome in children previously vaccinated with live attenuated measles, mumps, rubella and varicella vaccine. Pediatr Infect Dis J 1997; 16 (6): 626-7
49. Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am 1996; 10 (3): 617-29
50. Tseng HF, Tan HF, Chang CK. Varicella vaccine safety, incidence of breakthrough, and factors associated with breakthrough in Taiwan. Am J Infect Control 2003; 31 (3): 151-6
51. Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13-38
52. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a daycare center despite vaccination. N Engl J Med. 2002 Dec 12; 347 (24): 1909-15
53. Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects: 10-year survey at pediatric clinic. Vaccine 2000; 18 (22): 2375-80
54. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287 (5): 606-11
55. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 2000; 6 (4): 451-4
56. Bolker BM, Grenfell BT. Impact of vaccination on the spatial correlation and persistence of measles dynamics. Proc Natl Acad Sci U S A. 1996 Oct 29; 93 (22): 12648-53
57. Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13-38
58. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003; 88: 862-9
59. Edmunds WJ, Brisson M, Gay NJ, et al. Varicella vaccination: a double-edged sword? Commun Dis Public Health 2002; 5 (3): 185-6
60. Gershon AA, Takahashi M, White CJ. Varicella vaccine. In: Plotkin SA, editor. Vaccines. 3rd ed. Philadelphia (PA): WB Saunders, 1999: 475-507
61. Nikas AA, Coplan PM, Kaplan KM, et al. Herpes zoster hospitalisation rates: 1990-2000. 21st annual meeting of the European Society for Pediatric and Infectious Diseases; 2003, 11
62. Levy-Bruhl D, Pebody R, Veldhuijzen I, et al. ESEN: a comparison of vaccination programmes. Part three: measles mumps and rubella. Euro Surveill 1998; 3 (12): 115-9
63. Saddier P, Floret D, Guess HA, et al. Cost of varicella in France: a study in day care centers. J Inf Dis 1998; 178 Suppl. 1: S58-63